Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 27 peer-reviewed journal articles Updated
Cardiology · LMNA-Related Cardiomyopathy

Understanding LMNA-Related Cardiomyopathy

At a Glance

LMNA-related cardiomyopathy is an inherited form of dilated cardiomyopathy that can weaken heart pumping and disrupt electrical signals. Regular rhythm and imaging checks, individualized ICD assessment, and genetic screening for close relatives help manage risk.

Being diagnosed with LMNA-related cardiomyopathy can feel overwhelming, especially because it often affects families and carries a unique set of risks compared to other types of heart disease [1][2]. However, understanding the specific “why” behind this condition is the first step in taking control of your health.

This condition is a type of familial dilated cardiomyopathy (DCM), meaning the heart chambers can enlarge with impaired contraction, and it is passed down through genes [3]. While it is a serious diagnosis that requires close monitoring, modern cardiology has developed specialized strategies to manage the risks and support your heart function for the long term [4][5].

Quick Definitions

  • LVEF (Left Ventricular Ejection Fraction): A measurement of how much blood the left ventricle pumps out.
  • AV Block: A delay in the electrical signals passing through the heart, causing a slow heartbeat.
  • NSVT: Nonsustained Ventricular Tachycardia, a brief rapid heart rhythm that stops on its own.
  • Pathogenic Variant: A genetic mutation known to cause disease.
  • VUS: Variant of Uncertain Significance, meaning there isn’t enough evidence to know if it causes disease.

The Role of the LMNA Gene

To understand this condition, it helps to think of your heart cells as tiny, high-pressure engines. Inside every cell is a nucleus, which acts as the control center. The LMNA gene provides the instructions for making proteins called lamin A and lamin C [6]. These proteins form a protective mesh or “scaffold” just inside the membrane of the nucleus [7].

This scaffold serves two vital purposes:

  1. Structural Strength: It keeps the nucleus strong so it can withstand the constant physical squeezing and stretching of the beating heart [8][9].
  2. Organization: It helps organize your DNA, ensuring that the right genes are turned on or off at the right time [10][11].

How Mutations Cause Disease

In LMNA-related cardiomyopathy, a mutation (a “typo” in the genetic code) makes the lamin proteins unstable. This leads to what scientists call nuclear fragility—the control center of the cell becomes physically weak [12].

As your heart beats, laboratory and mechanistic studies suggest the fragile nuclei in your heart cells may become deformed under the mechanical stress [13][14]. Over time, this repeated microscopic damage may contribute to:

  • Cell Loss: Heart muscle cells may stop working or die prematurely [15].
  • Fibrosis: The body tries to heal this damage by creating fibrosis (scar tissue). While scar tissue is tough, it cannot pump blood and can interfere with the heart’s electrical signals [16][17].
  • Electrical Instability: The damaged cells and scar tissue can cause “short circuits,” leading to dangerous heart rhythms or a slow heartbeat (conduction disease) [18][19].

Prevalence and Risk

LMNA mutations are one of the most common genetic causes of familial DCM. Research shows they account for approximately 5% to 8% of all cases where dilated cardiomyopathy runs in a family [1][20].

It is important to know that LMNA-related disease is “age-dependent.” This means that even if you have the gene, you might have a normal heart as a young adult, but the risk of developing symptoms increases as you get older, often appearing in the 30s or 40s [21][22]. While penetrance is high, the progression is variable and not every carrier follows the exact same path.

The Typical Patient Journey

The “journey” with LMNA-related cardiomyopathy is different for everyone, but it often involves a combination of electrical and structural changes:

  1. Early Electrical Changes: For many, the first sign isn’t a weak heart, but an abnormal EKG. This might include a slow heart rate (AV block) or a fluttering sensation called atrial fibrillation [22][23].
  2. Muscle Weakening: Over time, the heart may begin to enlarge and its pumping power (ejection fraction) may decrease [22].
  3. Heart Failure Symptoms: You may notice you get tired more easily or feel short of breath during activities that used to be easy [21].
  4. Rhythm Management: Because of the high risk of sudden “short circuits,” your care team will continually assess whether you need an ICD (implantable cardioverter-defibrillator) [4]. Doctors often discuss these earlier for LMNA patients than for other heart failure patients because the risk of rhythm issues can be high even when the heart’s pumping power seems “okay” [24][25].

Managing the Road Ahead

While this condition can progress, you are not powerless. Management focuses on protecting your heart and preventing sudden events:

  • Multidisciplinary Care: You should ideally be followed by a team that includes a genetic counselor and a cardiologist who specializes in electrophysiology (heart rhythms) and heart failure [3][2].
  • Frequent Monitoring: Expect regular EKGs, Holter monitors (wearable heart monitors), and imaging like echocardiograms or Cardiac MRI to catch changes early [1][21].
  • Family Protection: Once you have a diagnosis, your first-degree relatives (parents, siblings, and children) should be offered genetic testing. This “cascade screening” can save lives by identifying family members who need monitoring before they ever feel a symptom [1][26].

The emotional toll of a genetic diagnosis is real. It is normal to feel anxious about your future or your family’s future. Connecting with specialized care teams and patient support groups can help you navigate the uncertainties of this journey with the best possible evidence and support [27].

Common questions in this guide

What is LMNA-related cardiomyopathy?
LMNA-related cardiomyopathy is an inherited form of dilated cardiomyopathy caused by a disease-causing change in the LMNA gene. It can enlarge and weaken the heart chambers and interfere with the heart’s electrical signals, causing slow or irregular rhythms.
Why can an LMNA mutation cause heart rhythm problems?
LMNA changes can make the nucleus of heart cells fragile, and repeated mechanical stress may contribute to cell loss and scar tissue. Scar tissue can interrupt electrical signals, leading to conduction problems or dangerous abnormal rhythms.
What symptoms should I watch for with LMNA-related cardiomyopathy?
Possible symptoms include a fluttering or skipping heartbeat, lightheadedness, fainting, unusual tiredness, and shortness of breath during activity. Some people first show a slow or abnormal rhythm on an EKG without having noticeable symptoms.
Why might I need an ICD even if my ejection fraction is above 35%?
An implantable cardioverter-defibrillator may be discussed earlier in LMNA-related cardiomyopathy because dangerous ventricular rhythms can occur before severe pumping weakness. The decision is individualized and may consider fainting, brief episodes of a fast ventricular rhythm, conduction disease, scar tissue on cardiac MRI, the specific LMNA variant, and other findings.
Should my children, siblings, or parents have genetic testing?
If a disease-causing LMNA variant has been identified, first-degree relatives such as parents, siblings, and children should be offered genetic counseling and testing. Relatives who carry the variant may need regular heart monitoring even before symptoms appear.
What tests are used to monitor LMNA-related cardiomyopathy?
Care teams commonly use EKGs, wearable ambulatory monitors such as Holter monitors, echocardiograms, and cardiac MRI. The schedule depends on age, symptoms, genetic findings, heart function, and previous rhythm results.
What does a VUS in the LMNA gene mean?
A variant of uncertain significance, or VUS, is a genetic change for which there is not enough evidence to know whether it causes disease. A genetics professional interprets it alongside your personal and family history, and a VUS should not be used alone to make medical decisions.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific LMNA variant, and is it considered a 'truncating' or 'missense' mutation?
  2. 2.Given my current heart function, what is my estimated 5-year risk for serious heart rhythm issues?
  3. 3.Should we consider an ICD (defibrillator) now, even if my ejection fraction is still above 35%?
  4. 4.How often should I have an ambulatory ECG (Holter monitor) to check for silent rhythm changes?
  5. 5.Does my cardiac MRI show any signs of scarring (fibrosis), and how does that affect my risk?
  6. 6.Can you help me coordinate genetic testing and screening for my children and siblings?
  7. 7.Are there specific physical activities I should avoid to minimize stress on my heart cells?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (27)
  1. 1

    Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation.

    Hasselberg NE, Haland TF, Saberniak J, et al.

    European heart journal 2018; (39(10)):853-860 doi:10.1093/eurheartj/ehx596.

    PMID: 29095976
  2. 2

    Genetic testing and counseling for hypertrophic cardiomyopathy: An evidence-based practice resource of the National Society of Genetic Counselors.

    Miller EM, Brown E, Christian S, et al.

    Journal of genetic counseling 2025; (34(3)):e1993 doi:10.1002/jgc4.1993.

    PMID: 39484862
  3. 3

    Dilated Cardiomyopathy: A Genetic Journey from Past to Future.

    Newman NA, Burke MA

    International journal of molecular sciences 2024; (25(21)) doi:10.3390/ijms252111460.

    PMID: 39519012
  4. 4

    Risk predictors in a Spanish cohort with cardiac laminopathies. The REDLAMINA registry.

    Barriales-Villa R, Ochoa JP, Larrañaga-Moreira JM, et al.

    Revista espanola de cardiologia (English ed.) 2021; (74(3)):216-224 doi:10.1016/j.rec.2020.03.026.

    PMID: 32616434
  5. 5

    Lamin A/C Cardiomyopathy: Implications for Treatment.

    Chen SN, Sbaizero O, Taylor MRG, Mestroni L

    Current cardiology reports 2019; (21(12)):160 doi:10.1007/s11886-019-1224-7.

    PMID: 31773301
  6. 6

    Nuclear envelope proteins modulate proliferation of vascular smooth muscle cells during cyclic stretch application.

    Qi YX, Yao QP, Huang K, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2016; (113(19)):5293-8 doi:10.1073/pnas.1604569113.

    PMID: 27114541
  7. 7

    Nuclear damage in LMNA mutant iPSC-derived cardiomyocytes is associated with impaired lamin localization to the nuclear envelope.

    Wallace M, Zahr H, Perati S, et al.

    Molecular biology of the cell 2023; mbcE21100527 doi:10.1091/mbc.E21-10-0527.

    PMID: 37585285
  8. 8

    Microtubule forces drive nuclear damage in LMNA cardiomyopathy.

    Pavlov DA, Heffler J, Suay-Corredera C, et al.

    bioRxiv : the preprint server for biology 2025; doi:10.1101/2024.02.10.579774.

    PMID: 38948795
  9. 9

    Spatial distribution of lamin A/C determines nuclear stiffness and stress-mediated deformation.

    Srivastava LK, Ju Z, Ghagre A, Ehrlicher AJ

    Journal of cell science 2021; (134(10)) doi:10.1242/jcs.248559.

    PMID: 34028539
  10. 10

    Lamin C is required to establish genome organization after mitosis.

    Wong X, Hoskins VE, Melendez-Perez AJ, et al.

    Genome biology 2021; (22(1)):305 doi:10.1186/s13059-021-02516-7.

    PMID: 34775987
  11. 11

    Lamin A/C-dependent chromatin architecture safeguards naïve pluripotency to prevent aberrant cardiovascular cell fate and function.

    Wang Y, Elsherbiny A, Kessler L, et al.

    Nature communications 2022; (13(1)):6663 doi:10.1038/s41467-022-34366-7.

    PMID: 36333314
  12. 12

    Altering lamina assembly reveals lamina-dependent and -independent functions for A-type lamins.

    Zwerger M, Roschitzki-Voser H, Zbinden R, et al.

    Journal of cell science 2015; (128(19)):3607-20 doi:10.1242/jcs.171843.

    PMID: 26275827
  13. 13

    Nuclear shape is affected differentially by loss of lamin A, lamin C, or both lamin A and C.

    Pho M, Berrada Y, Gunda A, Stephens AD

    microPublication biology 2024; (2024()) doi:10.17912/micropub.biology.001103.

    PMID: 38440331
  14. 14

    Eliminating elevated p53 signaling fails to rescue skeletal muscle defects or extend survival in lamin A/C-deficient mice.

    Kirby TJ, Zahr HC, Fong EHH, Lammerding J

    Cell death discovery 2024; (10(1)):245 doi:10.1038/s41420-024-01998-1.

    PMID: 38778055
  15. 15

    Mutant lamins cause nuclear envelope rupture and DNA damage in skeletal muscle cells.

    Earle AJ, Kirby TJ, Fedorchak GR, et al.

    Nature materials 2020; (19(4)):464-473 doi:10.1038/s41563-019-0563-5.

    PMID: 31844279
  16. 16

    Meta-analysis of the role of cardiac magnetic resonance in laminopathy.

    Shahshenas S, Anissian A, Jalali Nadoushan M, Soltanipur M

    Archives of cardiovascular diseases 2026; (119(5)):357-367 doi:10.1016/j.acvd.2026.02.003.

    PMID: 41966904
  17. 17

    Cardiac fibroblasts counterbalance cardiomyocytes in LMNA cardiomyopathy pathogenesis.

    Sikder K, Phillips E, Bouhrira N, et al.

    bioRxiv : the preprint server for biology 2025; doi:10.1101/2025.06.05.657412.

    PMID: 40692701
  18. 18

    The K219T-Lamin mutation induces conduction defects through epigenetic inhibition of SCN5A in human cardiac laminopathy.

    Salvarani N, Crasto S, Miragoli M, et al.

    Nature communications 2019; (10(1)):2267 doi:10.1038/s41467-019-09929-w.

    PMID: 31118417
  19. 19

    Characteristics of ventricular tachycardia and long-term treatment outcome in patients with dilated cardiomyopathy complicated by lamin A/C gene mutations.

    Hasebe Y, Fukuda K, Nakano M, et al.

    Journal of cardiology 2019; (74(5)):451-459 doi:10.1016/j.jjcc.2019.03.019.

    PMID: 31060954
  20. 20

    A case report of successful physiological pacing in a patient with lamin A/C cardiomyopathy.

    Chandra Mohan N, Foley P, Chandrasekaran B

    European heart journal. Case reports 2022; (6(8)):ytac324 doi:10.1093/ehjcr/ytac324.

    PMID: 36045645
  21. 21

    LMNA Cardiomyopathy: Important Considerations for the Heart Failure Clinician.

    Rosario KF, Karra R, Amos K, et al.

    Journal of cardiac failure 2023; (29(12)):1657-1666 doi:10.1016/j.cardfail.2023.08.016.

    PMID: 37659618
  22. 22

    Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers.

    Kumar S, Baldinger SH, Gandjbakhch E, et al.

    Journal of the American College of Cardiology 2016; (68(21)):2299-2307 doi:10.1016/j.jacc.2016.08.058.

    PMID: 27884249
  23. 23

    Intrinsic Atrial Myopathy Precedes Left Ventricular Dysfunction and Predicts Atrial Fibrillation in Lamin A/C Cardiomyopathy.

    Tremblay-Gravel M, Ichimura K, Picard K, et al.

    Circulation. Genomic and precision medicine 2023; (16(1)):e003480 doi:10.1161/CIRCGEN.121.003480.

    PMID: 36548481
  24. 24

    Missense and Non-Missense Lamin A/C Gene Mutations Are Similarly Associated with Major Arrhythmic Cardiac Events: A 20-Year Single-Centre Experience.

    Forleo C, Carella MC, Basile P, et al.

    Biomedicines 2024; (12(6)) doi:10.3390/biomedicines12061293.

    PMID: 38927500
  25. 25

    Genetic Risk of Arrhythmic Phenotypes in Patients With Dilated Cardiomyopathy.

    Gigli M, Merlo M, Graw SL, et al.

    Journal of the American College of Cardiology 2019; (74(11)):1480-1490 doi:10.1016/j.jacc.2019.06.072.

    PMID: 31514951
  26. 26

    Clinical Features of LMNA-Related Cardiomyopathy in 18 Patients and Characterization of Two Novel Variants.

    Ferradini V, Cosma J, Romeo F, et al.

    Journal of clinical medicine 2021; (10(21)) doi:10.3390/jcm10215075.

    PMID: 34768595
  27. 27

    Hypertrophic cardiomyopathy considerations for the managed care pharmacist.

    Taddei-Allen P

    The American journal of managed care 2021; (27(6 Suppl)):S118-S125 doi:10.37765/ajmc.2021.88629.

    PMID: 33861536

This page explains LMNA-related cardiomyopathy, heart-rhythm monitoring, and family screening for educational purposes. It does not replace advice from your cardiologist, electrophysiologist, genetic counselor, or other healthcare professional about your personal risk and care.

Get notified when new evidence is published on Familial dilated cardiomyopathy with conduction defect due to LMNA mutation.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.